U.S.-EU Free Trade Deal Achievable, Brilliant Says

July 9 (Bloomberg) -- Myron Brilliant, senior vice president for international affairs at the Washington-based U.S. Chamber of Commerce, talks about the prospects for the free-trade negotiations between the European Union and the U.S. He speaks from New York with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg)

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
09:50 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn